Table of Contents
- Table of Contents
- Health Industry Insights Opinion
- In This Report
- Brief Description of the Solution
- Situation Overview
- Current Environment
- Table: Cardiovascular Adverse Events for Selected Drugs
- Management Challenges
- Emerging Process Keystones and Other Supporting Knowledge Infrastructure
- The $1,000 Genome
- Whole Genome Sequences from Individuals
- Advances in Systems Biology
- Advances in Translational Medicine
- Potential Catalysts to Accelerate Personalized Medicine Adoption
- Large-Scale Genotyping of Clinical Trial Participants
- Routine Post-Clinical Trial Genotyping for All Adverse Event Patients
- Development of Minable EHRs Containing Whole Genome Data for Adverse Event Patients
- Biobanking of Adverse Event Tissues
- Strategic Efforts to Watch
- Success Factors
- Factors Affecting Adoption
- Future Outlook
- Remaining Challenges
- Market Trends
- Potential Pitfalls
- Essential Guidance
- Actions to Consider
- Pharma
- Healthcare Providers
- Healthcare Payers
- Patient Advocacy Groups
- Learn More
- Related Research
- Synopsis
|
Related Report
|
View Cart
